{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036406","form_type":"8-K","ticker":"NUS","cik":"0001021561","company_name":"NU SKIN ENTERPRISES, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.909625+00:00","generated_at":"2026-05-31T10:39:16.252412+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Nu Skin Q2 revenue $439M, GAAP EPS $(2.38) on $141M impairment charge; guides FY24 revenue $1.73-1.81B","bullets":["Revenue $439.1M, down 12.2% YoY; FX headwind of 4.2% ($21.0M).","GAAP EPS $(2.38) vs $0.54 prior-year; adjusted EPS $0.21 excluding restructuring and impairment charges.","Recorded $141M non-cash goodwill and intangibles impairment charge due to stock price decline.","Rhyz segment revenue $67.8M (+32.3% YoY); core Nu Skin customers down 14% to 893,514.","Q3 2024 revenue guidance $430-$465M; FY2024 revenue narrowed to $1.73-$1.81B, adjusted EPS $0.75-$0.95."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036406","json":"https://secwatch.observer/filing/0001140361-24-036406.json","markdown":"https://secwatch.observer/filing/0001140361-24-036406.md","text":"https://secwatch.observer/filing/0001140361-24-036406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124036406/0001140361-24-036406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1021561/000114036124036406/ef20033803_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:39:16.252412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}